|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current guidelines for the management of non-alcoholic fatty liver disease:A systematic review with comparative analysis显示文摘The current epidemic of non-alcoholic fatty liver disease(NAFLD) is reshaping the field of hepatology all around the world.The widespread diffusion of metabolic risk factors such as obesity,type2-diabetes mellitus,and dyslipidemia has led to a worldwide diffusion of NAFLD.In parallel to the increased availability of effective anti-viral agents,NAFLD is rapidly becoming the most common cause of chronic liver disease in Western Countries,and a similar trend is expected in Eastern Countries in the next years.This epidemic and its consequences have prompted experts from all over the word in identifying effective strategies for the diagnosis,management,and treatment of NAFLD.Different scientific societies from Europe,America,and Asia-Pacific regions have proposed guidelines based on the most recent evidence about NAFLD.These guidelines are consistent with the key elements in the management of NAFLD,but still,show significant difference about some critical points.We reviewed the current literature in English language to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences.We distinguished guidelines from 5 different scientific societies whose reputation is worldwide recognised and who are representative of the clinical practice in different geographical regions.Differences were noted in: the definition of NAFLD,the opportunity of NAFLD screening in high-risk patients,the noninvasive test proposed for the diagnosis of NAFLD and the identification of NAFLD patients with advanced fibrosis,in the follow-up protocols and,finally,in the treatment strategy(especially in the proposed pharmacological management).These difference have been discussed in the light of the possible evolution of the scenario ofNAFLD in the next years. | Simona Leoni Francesco Tovoli Lucia Napoli Ilaria Serio Silvia Ferri Luigi Bolondi | 2018 | World Journal of Gastroenterology2018，24，30： | 42 |
| 2 | Hepatocellular adenoma: An unsolved diagnostic enigma显示文摘Hepatocellular adenoma (HCA) is a rare benign liver tumour associated with the use of oral contraceptives or other steroid medications which occurs predominantly in young and middle-aged women. Unlike other benign liver tumours, an HCA may be complicated by bleeding and malignant transformation. HCAs have been divided into four subtypes based on molecular and pathological features: hepatocyte nuclear factor 1α-mutated HCA, inflammatory HCA,β-catenin-mutated HCA, and unclassified HCA.β-cateninmutated HCA has the highest risk of haemorrhage or malignant transformation. In the latest upgrade of the guidelines regarding the management of benign liver tumours published in 2016 by the European Association for the Study of the Liver, magnetic resonance imaging (MRI) was recognized to be superior to all other imaging modalities in detecting HCAs and in being able to subtype HCAs up to 80%, with positive identification of 1α-mutated HCA or inflammatory HCA achievable with > 90% specificity. This review analyzed the imaging features of HCA using MRI with hepato-specific contrast agents, focusing on the limitations in the HCA characterization. | Matteo Renzulli Alfredo Clemente Francesco Tovoli Salvatore Cappabianca Luigi Bolondi Rita Golfieri | 2019 | World Journal of Gastroenterology2019，25，20： | 12 |
| 3 | Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma显示文摘Epithelioid hemangioendothelioma(EH)is a rare tumor arising from the vascular endothelial cells of soft tissue or visceral organs.The most common visceral site is the liver,where it is often involved in a multifocal man-ner known as hepatic EH(HEH).Surgical resection with curative intent represents the gold standard therapy.When surgery is not feasible,or in cases of metastatic disease,no standard medical treatment is currently indicated.In small series,drugs with anti-angiogenic activity(such as bevacizumab,sorafenib,thalidomide,and lenalidomide)have been proposed with promising results.We describe a 73-year-old man with multifocal non-resectable HEH treated with lenalidomide.Disease status was evaluated by abdominal ultrasound and magnetic resonance every four months.The patient was treated for a total of 39 mo with prolonged disease stabilization and,at the time of writing,is still under treatment with a good tolerance profile.During a short period of treatment discontinuation,the disease showed slight progression that immediately resolved after the reintroduction of lenalidomide.Lenalidomide may represent a valid treatment option for HEH due to its anti-angiogenic and antineoplastic activities.This preliminary result merits further study in a large series. | Maria Caterina Pallotti Margherita Nannini Claudio Agostinelli Simona Leoni Valerio Di Scioscio Anna Mandrioli Cristian Lolli Maristella Saponara Stefano Pileri Luigi Bolondi Guido Biasco Maria Abbondanza Pantaleo | 2014 | World Journal of Gastroenterology2014，20，22： | 9 |
| 4 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions显示文摘 | Luigi Bolondi Andrew Burroughs Jean-Fran?ois Dufour Peter Galle Vincenzo Mazzaferro Fabio Piscaglia Jean Raoul Bruno Sangro | 2012 | Semin Liver Dis2012，，04： | 7 |
| 5 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 6 | Intraoperative thromboelastography as a tool to predict postoperative thrombosis during liver transplantation显示文摘BACKGROUND Thromboembolic complications are relatively common causes of increased morbidity and mortality in the perioperative period in liver transplant patients.Early postoperative portal vein thrombosis(PVT,incidence 2%-2.6%)and early hepatic artery thrombosis(HAT,incidence 3%-5%)have a poor prognosis in transplant patients,having impacts on graft and patient survival.In the present study,we attempted to identify the predictive factors of these complications for early detection and therefore monitor more closely the patients most at risk of thrombotic complications.AIM To investigate whether intraoperative thromboelastography(TEG)is useful in detecting the risk of early postoperative HAT and PVT in patients undergoing liver transplantation(LT).METHODS We retrospectively collected thromboelastographic traces,in addition to known risk factors(cold ischemic time,intraoperative requirement for red blood cells and fresh-frozen plasma transfusion,prolonged operating time),in 27 patients,selected among 530 patients(≥18 years old),who underwent their first LT from January 2002 to January 2015 at the Liver University Transplant Center and developed an early PVT or HAT(case group).Analyses of the TEG traces were performed before anesthesia and 120 min after reperfusion.We retrospectively compared these patients with the same number of nonconsecutive control patients who underwent LT in the same study period without developing these complications(1:1 match)(control group).The chosen matching parameters were:Patient graft and donor characteristics[age,sex,body mass index(BMI)],indication for transplantation,procedure details,United Network for Organ Sharing classification,BMI,warm ischemia time(WIT),cold ischemia time(CIT),the volume of blood products transfused,and conventional laboratory coagulation analysis.Normally distributed continuous data are reported as the mean±SD and compared using one-way Analysis of Variance(ANOVA).Nonnormally distributed continuous data are reported as the median(interquartile range)and compared using the Mann-Whitney test.Categorical variables were analyzed with Chi-square tests with Yates correction or Fisher’s exact test depending on best applicability.IBM SPSS Statistics version 24(SPSS Inc.,Chicago,IL,United States)was employed for statistical analysis.Statistical significance was set at P<0.05.RESULTS Postoperative thrombotic events were identified as early if they occurred within 21 d postoperatively.The incidence of early hepatic artery occlusion was 3.02%,whereas the incidence of PVT was 2.07%.A comparison between the case and control groups showed some differences in the duration of surgery,which was longer in the case group(P=0.032),whereas transfusion of blood products,red blood cells,fresh frozen plasma,and platelets,was similar between the two study groups.Thromboelastographic parameters did not show any statistically significant difference between the two groups,except for the G value measured at basal and 120’postreperfusion time.It was higher,although within the reference range,in the case group than in the control group(P=0.001 and P<0.001,respectively).In addition,clot lysis at 60 min(LY60)measured at 120’postreperfusion time was lower in the case group than in the control group(P=0.035).This parameter is representative of a fibrinolysis shutdown(LY60=0%-0.80%)in 85%of patients who experienced a thrombotic complication,resulting in a statistical correlation with HAT and PVT.CONCLUSION The end of surgery LY60 and G value may identify those recipients at greater risk of developing early HAT or PVT,suggesting that they may benefit from intense surveillance and eventually anticoagulation prophylaxis in order to prevent these serious complications after LT. | Lesley De Pietri Roberto Montalti Giuliano Bolondi Valentina Serra Fabrizio Di Benedetto | 2020 | World Journal of Transplantation2020，10，11： | 5 |
| 7 | Predictive factors of short term outcome after liver transplantation: A review显示文摘Liver transplantation represents a fundamental therapeutic solution to end-stage liver disease. The need for liver allografts has extended the set of criteria for organ acceptability, increasing the risk of adverse outcomes. Little is known about the early postoperative parameters that can be used as valid predictive indices for early graft function, retransplantation or surgical reintervention, secondary complications, long intensive care unit stay or death. In this review, we present state-of-the-art knowledge regarding the early posttransplantation tests and scores that can be applied during the first postoperative week to predict liver allograft function and patient outcome, thereby guiding the therapeutic and surgical decisions of the medical staff. Post-transplant clinical and biochemical assessment of patients through laboratory tests(platelet count, transaminase and bilirubin levels, INR, factor V, lactates, and Insulin Growth Factor 1) and scores(model for end-stage liver disease, acute physiology and chronic health evaluation, sequential organ failure assessment and model of early allograft function have been reported to have good performance, but they only allow late evaluation of patient status and graft function, requiring days to be quantified. The indocyanine green plasma disappearance rate has long been used as a liver function assessment technique and has produced interesting, although not univocal, results when performed between the 1th and the 5th day after transplantation. The liver maximal function capacity test is a promising method of metabolic liver activity assessment, but its use is limited by economic cost and extrahepatic factors. To date, a consensual definition of early allograft dysfunction and the integration and validation of the above-mentioned techniques, through the development of numerically consistent multicentric prospective randomised trials, are necessary. The medical and surgical management of transplanted patients could be greatly improved by using clinically reliable tools to predict early graft function. | Giuliano Bolondi Federico Mocchegiani Roberto Montalti Daniele Nicolini Marco Vivarelli Lesley De Pietri | 2016 | World Journal of Gastroenterology2016，22，26： | 5 |
| 8 | Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”显示文摘 | E. Terzi R. Golfieri F. Piscaglia M. Galassi A. Dazzi S. Leoni E. Giampalma M. Renzulli L. Bolondi | 2012 | Journal of Hepatology2012，，6： | 4 |
| 9 | Significance of serum and hepatic micro RNA ‐122 levels in patients with non‐alcoholic fatty liver disease显示文摘 | Hisamitsu Miyaaki Tatsuki Ichikawa Yasuhiro Kamo Naota Taura Takuya Honda Hidetaka Shibata Maddalena Milazzo Francesca Fornari Laura Gramantieri Luigi Bolondi Kazuhiko Nakao | 2014 | Liver Int2014，，7： | 4 |
| 10 | Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) - Update 2008显示文摘 | M Claudon D Cosgrove T Albrecht L Bolondi M Bosio F Calliada J.-M Correas K Darge C Dietrich M D’Onofrio D Evans C Filice L Greiner K J?ger N Jong E Leen R Lencioni D Lindsell A Martegani S Meairs C Nols?e F Piscaglia P Ricci G Seidel B Skjoldbye L Solbia | 2008 | Ultraschall in Med2008，，01： | 4 |
| 11 | Leitlinien für den Gebrauch von Ultraschallkontrastmitteln - Januar 2004显示文摘 | T Albrecht M Blomley L Bolondi M Claudon J.-M Correas D Cosgrove L Greiner K J?ger N Jong E Leen R Lencioni D Lindsell A Martegani L Solbiati L Thorelius F Tranquart H Weskott T Whittingham | 2004 | Ultraschall in Med2004，，04： | 3 |
| 12 | Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) - Update 2008显示文摘 | M Claudon D Cosgrove T Albrecht L Bolondi M Bosio F Calliada J.-M Correas K Darge C Dietrich M D'Onofrio D Evans C Filice L Greiner K J?ger N Jong E Leen R Lencioni D Lindsell A Martegani S Meairs C Nols?e F Piscaglia P Ricci G Seidel B Skjoldbye L Solbia | 2008 | Ultraschall in Med2008，，01： | 3 |
| 13 | Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma<!-- Doctopic: CAN -->显示文摘 | Alessandro Cucchetti Fabio Piscaglia Matteo Cescon Antonio Colecchia Giorgio Ercolani Luigi Bolondi Antonio D. Pinna | 2013 | Journal of Hepatology2013，，2： | 3 |
| 14 | Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group显示文摘 | Simona Leoni Fabio Piscaglia Ilaria Serio Eleonora Terzi Irene Pettinari Luca Croci Sara Marinelli Francesca Benevento Rita Golfieri Luigi Bolondi | 2014 | Digestive and Liver Disease2014，，： | 2 |
| 15 | Clinical and diagnostic aspects of gluten related disorders显示文摘Gluten is one of the most abundant and widely distributed components of food in many areas. It can be included in wheat, barley, rye, and grains such as oats, barley, spelt, kamut, and triticale. Gluten-containinggrains are widely consumed; in particular, wheat is one of the world's primary sources of food, providing up to 50% of the caloric intake in both industrialized and developing countries. Until two decades ago, celiac disease(CD) and other gluten-related disorders were believed to be exceedingly rare outside of Europe and were relatively ignored by health professionals and the global media. In recent years, however, the discovery of important diagnostic and pathogenic milestones led CD from obscurity to global prominence. In addition, interestingly, people feeding themselves with glutenfree products greatly outnumber patients affected by CD, fuelling a global consumption of gluten-free foods with approximately $2.5 billion in United States sales each year. The acknowledgment of other medical conditions related to gluten that has arisen as health problems, providing a wide spectrum of gluten-related disorders. In February 2011, a new nomenclature for gluten-related disorders was created at a consensus conference in London. In this review, we analyse innovations in the field of research that emerged after the creation of the new classification, with particular attention to the new European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for CD and the most recent research about non-celiac gluten sensitivity. | Francesco Tovoli Chiara Masi Elena Guidetti Giulia Negrini Paola Paterini Luigi Bolondi | 2015 | World Journal of Clinical Cases2015，3，3： | 2 |
| 16 | Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation显示文摘 | Fabio Piscaglia Alice Gianstefani Matteo Ravaioli Rita Golfieri Alberta Cappelli Emanuela Giampalma Elisabetta Sagrini Grazia Imbriaco Antonio Daniele Pinna Luigi Bolondi | 2010 | Liver Transpl2010，，： | 2 |
| 17 | Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population显示文摘 | Alessandro Cucchetti MD Fabio Piscaglia MD Eugenio Caturelli MD Luisa Benvegnù MD Marco Vivarelli MD Giorgio Ercolani MD Matteo Cescon MD Matteo Ravaioli MD Gian Luca Grazi MD Luigi Bolondi MD Antonio Daniele Pinna MD | 2009 | Annals of Surgical Oncology2009，，2： | 2 |
| 18 | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization显示文摘 | J.-L. Raoul B. Sangro A. Forner V. Mazzaferro F. Piscaglia L. Bolondi R. Lencioni | 2010 | Cancer Treatment Reviews2010，，3： | 2 |
| 19 | Hepatocellular carcinoma:epidemiology and clinical aspects显示文摘 | Mazzanti R Gramantieri L Bolondi L | | 0，，： | 1 |
| 20 | EFSUMB Study Group Guide lines for the use of contrast agent sinultrasound显示文摘 | Albrecht T Blomley M Bolondi L | 2004 | Ultraschall Med2004，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员